v3.26.3
Segment - Summary of Reconciles Reported Revenues to Net (Loss) Income under Significant Expense Principle (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Collaboration revenue $ 0     $ 0     $ 20,000 $ 0
Research and development 34,316     22,279     118,446 64,531
Selling, general and administrative 9,770     7,707     30,661 22,059
Loss from operations (44,086)     (29,986)     (129,107) (86,590)
Interest income 3,851     3,061     12,400 8,870
Net loss (40,235) $ (56,615) $ (19,857) (26,925) $ (26,732) $ (24,063) (116,707) (77,720)
RAP-219 Program External Expenses                
Segment Reporting [Line Items]                
Research and development 17,481     8,733     67,390 26,381
Preclinical Programs External Expenses                
Segment Reporting [Line Items]                
Research and development 4,473     4,474     13,632 12,442
R & D Personnel-Related Costs (Including Stock-based Compensation)                
Segment Reporting [Line Items]                
Research and development 10,559     7,381     31,836 20,833
Other Costs                
Segment Reporting [Line Items]                
Research and development 1,803     1,691     5,588 4,875
G & A Personnel Related Costs (Including Stock-based Compensation)                
Segment Reporting [Line Items]                
Selling, general and administrative 7,486     5,487     21,554 15,491
Professional and Consulting Costs                
Segment Reporting [Line Items]                
Selling, general and administrative 1,459     1,322     6,594 3,906
Facility Related and Other                
Segment Reporting [Line Items]                
Selling, general and administrative $ 825     $ 898     $ 2,513 $ 2,662